Lihou Dong

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Bixia Tang, Xieqiao Yan, Xinan Sheng et al. · Journal of Hematology & Oncology · 2019 · 185 citations · Full text

Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study

Jianliang Yang, Lihou Dong, Sheng Yang et al. · European Journal of Cancer · 2020 · 65 citations

Radiation Oncology, Recurrent Malignancies, Malignant Disease +9

Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody

Jie Fu, Fang Wang, Lihou Dong et al. · Acta Pharmacologica Sinica · 2017 · 53 citations · Full text

Autoimmune Disease, Preclinical Evaluation, Apoptosis +10

Preclinical safety profile of disitamab vedotin：a novel anti-HER2 antibody conjugated with MMAE

Jing Jiang, Shenjun Li, Xiaolei Shan et al. · Toxicology Letters · 2019 · 45 citations

Medicine, Immunology, Therapeutic Efficacy +6

HER2-targeted antibody drug conjugates for ovarian cancer therapy

Jing Jiang, Lihou Dong, Lei Wang et al. · European Journal of Pharmaceutical Sciences · 2016 · 40 citations

Drug Targeting, Ovarian Cancer Therapy, Tumor Targeting +4